EUCODIS Bioscience developed enzyme and enzymatic production method for PrEP Biopharm drug intermediate

EUCODIS Bioscience, an Austrian biotechnology company with strong expertise in industrial enzyme development, announces the completion of a development project for PrEP Biopharm Limited. In this collaboration, EUCODIS Bioscience developed an enzymatic method for production of a drug intermediate of PrEP-001, an immunomodulator for the prevention of the common cold and influenza and supplied key consumables for the GMP manufacturing process.

PrEP Biopharm Limited is a U.K. based clinical stage, biopharmaceutical company focused on the prevention of respiratory viral infections. Their lead program, PrEP-001, is a nasally administered, broad-spectrum agent that leverages the innate immune response to prevent upper respiratory tract viral infections. Successful human proof-of-concept trials with the compound have been completed demonstrating protection against rhinovirus-16 and influenza H3N2.

EUCODIS Bioscience has screened for, identified and developed an enzyme which is needed for enzymatic production of PrEP-001 intermediates. This involved set-up and up-scale of enzyme production, development of down-stream processing methods to obtain ≥ 96% purity and immobilisation of the target enzyme. Furthermore, EUCODIS Bioscience has established the enzymatic method to manufacture the drug intermediates under ISO9001 and has co-ordinated the transfer to GMP production.

Dr. Karl Hübler, CEO of EUCODIS Bioscience stated, “We are glad to be part of this exciting project. EUCODIS Bioscience was able to contribute its profound strengths in the full spectrum of enzyme identification, development and industrial manufacture.”

PrEP Biopharm’s Co-founder and CEO, - Ryan Muldoon, added, “We are pleased to have found such a reliable partner in EUCODIS Bioscience to set and scale up the enzymatic production of our intermediates. Eucodis technical expertise related to enzyme development and exceptional service and project management ensured the success of this project.”

About PrEP Biopharm
PrEP Biopharm Limited is a development stage biopharmaceutical company focused on the prevention of respiratory infections. The privately held company is developing and expects to commercialize products for the prevention of respiratory viral infections. The company is headquartered in London, England.

About EUCODIS Bioscience
EUCODIS Bioscience delivers high-performance enzyme solutions for highly specific applications in biopharma, fine chemicals, cosmetics and other industries. With a portfolio of over 50 enzymes including innovative lipases, beta-lactamases, peroxidases and other enzymes EUCODIS Bioscience has a proven track record of providing customized enzyme solutions. EUCODIS Bioscience also offers customized services in recombinant protein and enzyme production by covering the whole spectrum from bioprocess development up to industrial-scale manufacture of target proteins. EUCODIS Bioscienceis a privately owned company with its head quarter in Vienna, Austria.

Press contact
EUCODIS Bioscience GmbH
Campus Vienna Biocenter II
Tel: + 43 1 8900804
Fax: +43 1 8900804 ext. 11
Email: office(at)

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)